Back to Peptides
Hormone FDA Approved

Lanreotide

A long-acting somatostatin analog marketed as Somatuline Depot and used in neuroendocrine and acromegaly-related care.

Somatostatin AnalogFDA ApprovedAcromegalyNeuroendocrine

Also referenced as: Somatuline Depot, Lanreotide Acetate

Status
FDA Approved

This peptide maps to at least one regulated medical product or label context in the United States.

Category
Hormone

This profile is grouped by its dominant research and market lane, not by vendor shelf placement.

Aliases
2

Somatuline Depot, Lanreotide Acetate

Signal depth
High

FDA label signal · 124 trials · 1217 PubMed results

What lanreotide is

Lanreotide is a long-acting somatostatin analog best known in the United States as Somatuline Depot.

Why it matters

It rounds out the approved somatostatin-analog side of the peptide library and gives users a more complete picture of serious peptide therapeutics in endocrine medicine.

Regulatory context

Lanreotide is FDA approved in the United States.

Practical reading note

When a peptide has deep real-world use in medicine, it often deserves a page even if it is not a gray-market conversation magnet.